fungloz amphotericin b (amphotericin) 10mg lozenge bottle
aspen pharma pty ltd - amphotericin b, quantity: 10 mg - lozenge - excipient ingredients: acacia; mannitol; polyvinyl alcohol; saccharin sodium; sodium cyclamate; purified talc; stearic acid; flavour - treatment of candidal infections of the oral and perioral areas including oral thrush, angular cheilitis, denture stomatitis and in other conditions of the mouth, throat and tongue complicated by the overgrowth of candida albicans.
ambisome- amphotericin b injection, powder, lyophilized, for solution
astellas pharma us, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - amphotericin b 50 mg in 12.5 ml - amb isome is indicated for the following: see dosage and administration for recommended doses by indication. amb isome is contraindicated in those patients who have demonstrated or have a known hypersensitivity to amphotericin b deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.
abelcet- amphotericin b, dimyristoylphosphatidylcholine, dl- and dimyristoylphosphatidylglycerol, dl- injection
leadiant biosciences, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe), dimyristoylphosphatidylcholine, dl- (unii: u86zgc74v5) (dimyristoylphosphatidylcholine, dl- - unii:u86zgc74v5), dimyristoylphosphatidylglycerol, dl- (unii: bi71wt9p3r) (dimyristoylphosphatidylglycerol, dl- - unii:bi71wt9p3r) - amphotericin b 5 mg in 1 ml - abelcet ® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin b therapy. this is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin b therapy (see description of clinical studies). description of clinical studies fungal infections data from 473 patients were pooled from three open-label studies in which abelcet ® was provided for the treatment of patients with invasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin b, or who had preexisting nephrotoxicity. results of these studies demonstrated effectiveness of abelcet ® in the treatment of invasive fungal infections as a second line therapy. patients were defined by their individual physician as being refractory to or failing conventional amphotericin b therapy based on overall clinical judgement after receiving a minimu
amphotericin b for injection, usp powder for solution
sterimax inc - amphotericin b - powder for solution - 50mg - amphotericin b 50mg - polyenes
amphotec- amphotericin b injection, lipid complex
intermune, inc. - amphotericin b (unii: 7xu7a7droe) (amphotericin b - unii:7xu7a7droe) - injection, lipid complex - 50 mg in 10 ml - amphotec is indicated for the treatment of invasive aspergillosis in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin b deoxycholate in effective doses, and in patients with invasive aspergillosis where prior amphotericin b deoxycholate therapy has failed. amphotec should not be administered to patients who have documented hypersensitivity to any of its components, unless, in the opinion of the physician, the advantages of using amphotec outweigh the risks of hypersensitivity.
amphotericin b injection
asence pharma private limited sarabhai campus dr. vikram sarabhai marg wadi - amphotericin b - injection - amphotericin 50mg - antimycotics for systemic use: antibiotics
ambisome
gilead sciences israel ltd - amphotericin b - powder for concentrate for infusion - amphotericin b 50 mg/vial - amphotericin b - amphotericin b - antifungal antibiotic for the treatment of severe systemic and/or deep mycoses where toxicity precludes the use of conventional systemic amphotericin b in effective dosages. this drug should not be used to treat the common clinically inapparent forms of fungal disease which show only positive skin or serologic tests. ambisome is also indicated for the treatment of systemic fungal infections in immunocompromised patients (e.g. patients with aids or cancer). ambisome is also indicated for the primary therapy of visceral leishmaniasis in immunocompetent patients and immunocompromised patients (e.g. hiv positive). empirical treatment of presumed fungal infection in febrile neutropenic patients.
ambisome liposomal amphotericin b 50 mg powder for concentrate for dispersion for infusion
gilead sciences ireland uc - amphotericin b - concentrate for solution for infusion - 50 milligram(s) - antibiotics; amphotericin b
ambisome
gilead sciences (nz) - amphotericin b 50mg - powder for injection - 50 mg - active: amphotericin b 50mg excipient: cholesterol hydrochloric acid alpha-tocopherol distearoylphosphatidylglycerol phosphatidylcholines, soya, hydrogenated phosphatidylglycerols as sodium salt sodium hydroxide sodium succinate sucrose - ambisome is indicated for: · prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for · the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b. ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.
ambisome liposomal amphotericin b 50 milligram concentrate for soln for inf
gilead sciences international - amphotericin b - concentrate for soln for inf - 50 milligram - antibiotics